Current Hypertension Reports

, Volume 6, Issue 5, pp 369–376

Dual blockade of the renin angiotensin system in diabetic and nondiabetic kidney disease

  • Niels H. Andersen
  • Carl E. Mogensen


Dual blockade of the renin angiotensin system is based on a principle of obtaining the broadest and most efficient blockade of the effects of angiotensin II, by using the combination of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II-receptor blocker (ARB). By combining two, different pharmacologic principles and inhibiting both the ACE and the angiotensin II type 1 receptor, it seems possible to block both the production and the action of angiotensin II, which would serve as efficient antihypertensive therapy. Exploring the beneficial effects of dualblockade therapy is a work in rapid progress, in both diabetic and non-diabetic nephropathy. But evidence is also emerging in cardiovascular medicine, an overview of which is provided in this article.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Balcells E, Meng QC, Johnson WH Jr, et al.: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997, 273:H1769-H1774.PubMedGoogle Scholar
  2. 2.
    Ihara M, Urata H, Kinoshita A, et al.: Increased chymasedependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999, 33:1399–1405.PubMedGoogle Scholar
  3. 3.
    Burnier M, Brunner HR: Angiotensin II receptor antagonists. Lancet 2000, 355:637–645.PubMedCrossRefGoogle Scholar
  4. 4.
    Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004–1010.PubMedCrossRefGoogle Scholar
  5. 5.
    Parving HH, Lehnert H, Brochner-Mortensen J, et al.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.PubMedCrossRefGoogle Scholar
  6. 6.
    Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.PubMedCrossRefGoogle Scholar
  7. 7.
    Nio Y, Matsubara H, Murasawa S, et al.: Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995, 95:46–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Ohkubo N, Matsubara H, Nozawa Y, et al.: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997, 96:3954–3962.PubMedGoogle Scholar
  9. 9.
    Janiak P, Pillon A, Prost JF, Vilaine JP: Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension 1992, 20:737–745.PubMedGoogle Scholar
  10. 10.
    Sandmann S, Unger T: [Pathophysiological and clinical implications of AT(1)/AT(2) angiotensin II receptors in heart failure and coronary and renal failure]. Drugs 2002, 62 (Spec No 1):43–52. Comprehensive overview of the effects of the angiotensin II type 1 and 2 receptor by leading experts.PubMedCrossRefGoogle Scholar
  11. 11.
    Cao Z, Bonnet F, Candido R, et al.: Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002, 13:1773–1787.PubMedCrossRefGoogle Scholar
  12. 12.
    Rizkalla B, Forbes JM, Cooper ME, Cao Z: Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 2003, 14:3061–3071. New insights on the role of the AT2 receptor.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang X, Lassila M, Cooper ME, Cao Z: Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. Hypertension 2004, 43:276–281.PubMedCrossRefGoogle Scholar
  14. 14.
    Hilgers KF, Mann JF: ACE Inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002, 13:1100–1108.PubMedGoogle Scholar
  15. 15.
    Yagi S, Morita T, Katayama S: Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004, 27:129–135. New insights on the benefits of dual blockade. Experimental research.PubMedCrossRefGoogle Scholar
  16. 16.
    Hebert LA, Falkenhain ME, Nahman NS Jr, et al.: Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol 1999, 19:1–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440–1444.PubMedCrossRefGoogle Scholar
  18. 18.
    Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002, 25:95–100.PubMedCrossRefGoogle Scholar
  19. 19.
    Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002, 17:1019–1024.PubMedCrossRefGoogle Scholar
  20. 20.
    Rossing K, Jacobsen P, Pietraszek L, Parving HH: Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003, 26:2268–2274.PubMedCrossRefGoogle Scholar
  21. 21.
    Jacobsen P, Andersen S, Rossing K, et al.: Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003, 63:1874–1880.PubMedCrossRefGoogle Scholar
  22. 22.
    Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003, 14:992–999. Randomized, three-armed, crossover study. Despite potent doses of ACE inhibitor and ARBs, the dual blockade treatment was most effective.PubMedCrossRefGoogle Scholar
  23. 23.
    Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001, 59:2282–2289.PubMedGoogle Scholar
  24. 24.
    Agarwal R, Siva S, Dunn SR, Sharma K: Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002, 39:486–492.PubMedCrossRefGoogle Scholar
  25. 25.
    Tutuncu NB, Gurlek A, Gedik O: Efficacy of ACE inhibitors and ATII receptor blockers in patients with microalbuminuria: a prospective study. Acta Diabetol 2001, 38:157–161.PubMedCrossRefGoogle Scholar
  26. 26.
    Song JH, Lee SW, Suh JH, et al.: The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003, 60:318–326. Interesting design. No benefit of dual blockade in diabetic patients.PubMedGoogle Scholar
  27. 27.
    Russo D, Minutolo R, Pisani A, et al.: Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001, 38:18–25.PubMedGoogle Scholar
  28. 28.
    Woo KT, Lau YK, Wong KS, Chiang GS: ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 2000, 58:2485–2491.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferrari P, Marti HP, Pfister M, Frey FJ: Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002, 20:125–130.PubMedCrossRefGoogle Scholar
  30. 30.
    Berger ED, Bader BD, Ebert C, et al.: Reduction of proteinuria: combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition. J Hypertens 2002, 20:739–743.PubMedCrossRefGoogle Scholar
  31. 31.
    Kincaid-Smith P, Fairley K, Packham D: Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002, 17:597–601.PubMedCrossRefGoogle Scholar
  32. 32.
    Ruilope LM, Aldigier JC, Ponticelli C, et al.: Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000, 18:89–95.PubMedGoogle Scholar
  33. 33.
    Laverman GD, Navis G, Henning RH, et al.: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002, 62:1020–1025. Well-conducted, crossover study showing that high-dose monotherapy is inferior to dual blockade in the reduction of proteinuria.PubMedCrossRefGoogle Scholar
  34. 34.
    Campbell R, Sangalli F, Perticucci E, et al.: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003, 63:1094–1103.PubMedCrossRefGoogle Scholar
  35. 35.
    Luno J, Barrio V, Goicoechea MA, et al.: Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002, 62(Suppl 82):47–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Iodice C, Balletta MM, Minutolo R, et al.: Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. Kidney Int 2003, 63:2214–2221.PubMedCrossRefGoogle Scholar
  37. 37.
    Tylicki L, Rutkowski P, Renke M, Rutkowski B: Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis: short-term observation. Am J Nephrol 2002, 22:356–362.PubMedCrossRefGoogle Scholar
  38. 38.
    Rutkowski P, Tylicki L, Renke M, et al.: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004, 43:260–268. Only low-dose dual blockade study on patients with difficulty in tolerating ACE-inhibitions.PubMedCrossRefGoogle Scholar
  39. 39.
    Nakao N, Kimura G: Submaximal dose of trandolapril in the COOPERATE trial? Kidney Int 2003, 64:1921–1922.PubMedCrossRefGoogle Scholar
  40. 40.
    Hamroff G, Katz SD, Mancini D, et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999, 99:990–992.PubMedGoogle Scholar
  41. 41.
    McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056–1064.PubMedGoogle Scholar
  42. 42.
    Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675.PubMedCrossRefGoogle Scholar
  43. 43.
    Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. Major heart failure trial regarding eplerenone. Positive results with eplerenone despite optimized multipharmaceutical therapy in the placebo arm. Surprisingly safe treatment.PubMedCrossRefGoogle Scholar
  44. 44.
    McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771. Dual-blockade study in chronic heart failure patients, with candesartan added to concomitant ACE-inhibitor treatment.PubMedCrossRefGoogle Scholar
  45. 45.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. Major heart failure trial regarding valsartan, captopril, and the combination.PubMedCrossRefGoogle Scholar
  46. 46.
    Andersen NH, Knudsen ST, Poulsen PL, et al.: Dual blockade with candesartan cilexetil and lisinopril in hypertensive patients with diabetes mellitus: rationale and design. J Renin Angiotensin Aldosterone Syst 2003, 4:96–99.PubMedGoogle Scholar
  47. 47.
    Yusuf S: From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002, 89:18A-25A.PubMedCrossRefGoogle Scholar
  48. 48.
    Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831–1838. New, interesting data on the combination of eplerenone and enalapril.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Niels H. Andersen
    • 1
  • Carl E. Mogensen
    • 1
  1. 1.Department of Internal Medicine, Diabetes & Endocrinology, Aarhus HospitalAarhus University HospitalAarhus CDenmark

Personalised recommendations